156 related articles for article (PubMed ID: 3498959)
1. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
Kedar E; Zeira E; Lebendiker Z; Weiss DW; Katan R; Shouval D
Prog Clin Biol Res; 1987; 244():59-75. PubMed ID: 3498959
[No Abstract] [Full Text] [Related]
2. Long-term culture of LAK cells: expansion and activation signals.
Ochoa AC; Migliori RJ; Alter BJ; Sondel PM; Simmons RL; Bach FH
Prog Clin Biol Res; 1987; 244():289-99. PubMed ID: 3116557
[TBL] [Abstract][Full Text] [Related]
3. Studies on lymphokine activated killer cells in the rat: analysis of precursor and effector cell phenotype and relationship to natural killer cells.
Hiserodt JC; Vujanovic NL; Reynolds CW; Herberman RB; Cramer DV
Prog Clin Biol Res; 1987; 244():137-46. PubMed ID: 2958869
[No Abstract] [Full Text] [Related]
4. Natural killer cells and tumor immunity: 1985.
Herberman RB
Year Immunol; 1986; 2():254-60. PubMed ID: 3033946
[No Abstract] [Full Text] [Related]
5. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
Sondel PM; Hank JA; Kohler PC; Chen BP; Sosman J
Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
[No Abstract] [Full Text] [Related]
6. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans.
Topalian SL; Rosenberg SA
Important Adv Oncol; 1990; ():19-41. PubMed ID: 2182519
[No Abstract] [Full Text] [Related]
8. In vivo and in vitro activation of NK cytotoxicity with IL-2.
Ibayashi Y; Tokuda Y; Saks ER; Sarna GP; Golub SH
Prog Clin Biol Res; 1987; 244():275-85. PubMed ID: 3498954
[No Abstract] [Full Text] [Related]
9. [Use of interleukin 2-activated lymphocytes (LAK cells) in adoptive immunotherapy of neoplasms].
Robak T
Pol Tyg Lek; 1988 Nov; 43(47):1491-5. PubMed ID: 3266975
[No Abstract] [Full Text] [Related]
10. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
Spiess PJ; Yang JC; Rosenberg SA
J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of recombinant interleukin 2-activated killer cells against endometrial cancers.
Inoue M; Shimizu H; Shimizu C; Sasagawa T; Ueda G; Tanizawa O; Nishida M; Ishiwata I
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jan; 39(1):143-4. PubMed ID: 3493309
[No Abstract] [Full Text] [Related]
12. Natural killer cells.
Herberman RB
Prog Clin Biol Res; 1989; 288():161-7. PubMed ID: 2470107
[No Abstract] [Full Text] [Related]
13. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
15. [Induction of lymphokine-activated killer (LAK) cells from tumor-bearer splenocytes and their utilization in inhibition of tumor metastasis].
Okuno K; Nakamura T; Takagi H; Kokudo S; Iwasa Z; Yasutomi M
Nihon Gan Chiryo Gakkai Shi; 1985 Oct; 20(9):2055-62. PubMed ID: 3879262
[No Abstract] [Full Text] [Related]
16. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
17. [Interleukin-2 and cancer immunotherapy].
Ogarkov VI; Dobkin AI; Ryzhova EV; Okulov VB; Kiselev OI
Vopr Onkol; 1989; 35(2):141-50. PubMed ID: 2648678
[No Abstract] [Full Text] [Related]
18. Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow.
Merluzzi VJ; Trail PA; Last-Barney K
J Immunol; 1986 Oct; 137(8):2425-7. PubMed ID: 3531332
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
[TBL] [Abstract][Full Text] [Related]
20. [Effects of phenytoin on cell-mediated immunity].
Okamoto Y; Shimizu K; Tamura K; Miyao Y; Yamada M; Matsui Y; Tsuda N; Mogami H
No To Shinkei; 1987 Oct; 39(10):931-6. PubMed ID: 3501727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
